Cancer Progress

30+ Years of Scientific Discussions and Connections

Cancer Progress was started in 1989 with the goal of facilitating discussions of scientific progress within the context of development, regulatory, clinical, commercial and investment perspectives. A predecessor company of Lumanity, Defined Health, took over the event in 2011. Cancer Progress has historically featured two to three days of provocative, informative panel discussions with pivotal topics, frank discussions, vigorous debate, opportunities for audience questions and comments, and a partnering platform to enable meaningful connections and meetings with innovators, developers, and investors.

Cancer Progress: New Webinar Format

Our network of senior speakers will be holding a series of presentations and discussions throughout the year to share the latest on important issues impacting the biotech field today and provide a meaningful learning experience and valuable connections for participants. For more information on upcoming and past sessions, email us at contact@lumanity.com.

The New Burden of Proof: Platform, Concept and Relevance. Learn more and watch on-demand.
The Current “Not” State of the Art in Immuno-Oncology Combinations. Learn more and watch on-demand.
On the Backside of the Hype Cycle: Cancer Cell Therapy Companies Grappling with Lofty Expectations and Challenging Market Conditions. Learn more and watch on-demand.
Helping Make Tumors Hot: Have Cancer Vaccines Come in from the Cold? Learn more and watch on-demand.
Early Interception in Cancer: How Can the Current Medical and Industry Paradigm of Managing Advanced Cancer Be Turned on Its Head? Learn more and watch on-demand.

As I like to say, Cancer Progress is THE BEST non-academic cancer conference out there. Again proving your staggering insight!

Michael G. King Jr. Entrepreneur in Residence, Fortress Biotech Inc.

1 / 4

When we hear all the negatives from the experts on the cell therapies and COVID - let's think of Richard Feynman: "Science is the belief in the ignorance of the experts"

Mark Simon Managing Director, Torreya

2 / 4

I really enjoyed the meeting as usual - great topics and speakers. I look forward to next year's meeting!

Richard Brian Gaynor Sr. VP Global Development / Medical Affairs, Oncology Business Unit, Eli Lilly

3 / 4

Good array of opinions and technologies. Well curated.

Andrew Allen, MD, PhD President & CEO, Gritstone Oncology

4 / 4